1. The Pfizer/BioNTech vaccine for COVID-19 has been granted temporary or emergency use authorisation in multiple countries.
2. The vaccine was tested in 37,000 people and had a 95% efficacy rate across different age, ethnicity and health conditions.
3. Further research is needed to understand the long-term effects of the vaccine and its effectiveness in diverse populations.
The article “COVID-19: How effective is the Pfizer coronavirus vaccine?” published by the World Economic Forum provides an overview of the efficacy of the Pfizer/BioNTech vaccine for COVID-19. The article is generally reliable and trustworthy, as it provides evidence from a clinical trial with 37,000 participants that showed a 95% efficacy rate across different age, ethnicity and health conditions. However, there are some potential biases that should be noted.
First, the majority (83%) of participants in the trial were white, and most of the trial (77%) occurred in the USA (with additional participants in Argentina, Brazil and South Africa). This could lead to bias if results from this population do not accurately reflect results from other populations around the world. Additionally, pregnant women were excluded from the trial which could lead to bias if results from this population differ significantly from those included in the trial.
Second, while side effects reported by participants were generally mild to moderate and resolved within three days after injection, it is impossible to detect less common side effects until more people have received the vaccine over longer time periods. This means that there is still a risk of unknown side effects occurring which could affect trustworthiness of this article's claims about safety of this vaccine.
Finally, while this article does provide evidence for short term protection against COVID-19 after two doses of this vaccine, it does not provide any evidence regarding long term protection or effectiveness in diverse populations which would be necessary for full trustworthiness of its claims about efficacy of this vaccine.
In conclusion, while this article provides reliable information about short term efficacy of Pfizer/BioNTech's COVID-19 vaccine based on data from a clinical trial with 37,000 participants, there are potential biases due to exclusion of certain populations as well as lack of evidence regarding long term protection or effectiveness in diverse populations which should be taken into consideration when assessing trustworthiness and reliability of its claims about efficacy of this vaccine.